top of page
Search

Another new basal insulin, degludec, is available in Japan

  • Writer: Aaron Neinstein
    Aaron Neinstein
  • Sep 28, 2012
  • 1 min read

Japan has approved use of a new basal insulin from Novo Nordisk, insulin degludec.  It is being promoted by the company as having a duration of action up to 42 hours.  The press release is here.

Recent Posts

See All

ความคิดเห็น

  • Twitter
  • LinkedIn
  • Instagram

Dr. Aaron Neinstein is the Chief Medical Officer at Notable, the leading intelligent automation company for healthcare. In this role, he employs his care delivery expertise to strengthen Notable's product strategy and roadmap, ensure high-value customer outcomes, and foster healthcare community engagement on the value of AI and automation for patients and care teams.

 

Prior to joining Notable, Dr. Neinstein spent over a decade as a physician executives in digital health and informatics, most recently as Vice President of Digital Health at UCSF Health. He is an Associate Professor in the UCSF Division of Endocrinology, with a clinical practice focused on diabetes care.

© 2020 by Aaron Neinstein MD

bottom of page